Physician profile
Peter J Mulhern
NPI 1417932005
$3,063.30
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $1,585 · 2023: $571 · 2024: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $1,400.02 | 2021-2024 | |
| Stryker Corporation | $1,163.45 | 2021-2024 | Mako, Omnifit, Triathlon |
| Abbvie INC. | $211.64 | 2021-2022 | |
| Pacira Therapeutics, INC. | $40.60 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $40.17 | 2022-2023 | Seglentis |
| Endo Pharmaceuticals INC. | $34.57 | 2021 | |
| Smith+Nephew, INC. | $24.51 | 2021 | |
| Ferring Pharmaceuticals INC. | $23.64 | 2022 | |
| Bioventus LLC | $22.26 | 2022 | |
| Fidia Pharma USA INC. | $22.17 | 2022 | |
| Baudax Bio INC. | $16.29 | 2021 | |
| Depuy Synthes Sales INC. | $15.24 | 2021 | |
| Organogenesis INC. | $14.25 | 2023 | Puraply |
| Heraeus Medical, LLC. | $13.35 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $12.85 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $8.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mulhern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.